Verge Genomics

vergegenomics.com →

-61%

est. 2Y upside i

HealthcareSeries B

We use human data and AI to develop better drugs faster.

Rank

#2437

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Verge Genomics presents a moderate upside opportunity for a job seeker, but with a higher risk profile.

Last updated: March 10, 2026

Bull (20%)+200%

Verge's 'all-in-human' AI platform, Converge, successfully identifies multiple high-value drug targets that translate into successful clinical candidates through new and existing partnerships (e.g., Eli Lilly, AstraZeneca/Alexion). This leads to a strategic acquisition by a major pharmaceutical company or a successful IPO at a valuation of $1.2 billion (3x current valuation) within 3-5 years.

Base (45%)+50%

Verge continues to leverage its AI platform to generate promising drug candidates and secure additional, albeit modest, strategic partnerships. While the platform demonstrates its value in target discovery, clinical translation remains challenging, leading to a slower path to market. The company achieves an exit at approximately $605.6 million (1.5x current valuation) through a smaller acquisition or a later-stage funding round.

Bear (35%)-70%

Following the termination of its lead ALS candidate VRG50635, Verge struggles to demonstrate the clinical superiority of its AI-discovered drugs or secure new, significant partnerships. High capital intensity and burn rate lead to further funding challenges and a down round or acquisition at approximately $121.1 million (-70% from current valuation), severely impacting common stock value due to the substantial liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors hold $176 million in liquidation preferences ahead of common stock, based on total funding.

Dilution Risk

high

Given the very high capital intensity and clinical-stage nature, Verge Genomics will likely require additional significant funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

limited

Secondary market activity for Verge Genomics is low, with limited buyers or sellers, and typically only accessible to accredited investors.

Questions to Ask at the Interview

Strategic questions based on Verge Genomics's data — designed to show you've done your homework.

  • 1

    “Given the pivot to focus solely on the AI drug discovery platform after the VRG50635 termination, how is Verge Genomics strategically positioning itself to ensure its platform translates into successful clinical outcomes for partners, especially against well-funded competitors like Recursion Pharmaceuticals and Insitro?”

  • 2

    “With the high capital intensity of drug discovery and development, and the company not yet profitable, what is the long-term financial strategy to achieve sustainable profitability, particularly regarding the balance between internal pipeline development and revenue generation from strategic partnerships?”

  • 3

    “Considering the Series C valuation in 2023 and the significant preference stack, what is the company's anticipated timeline and strategy for a liquidity event (e.g., IPO or acquisition), and how does the current equity structure impact potential returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -61% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.